On February 20, 2018 INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, reported that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will present at the RBC Capital Markets Global Healthcare Conference as follows (Press release, Insys Therapeutics, FEB 20, 2018, View Source [SID1234524107]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, Feb. 22, 2018
Time: 10:00 a.m. Eastern Standard Time
Location: Lotte New York Palace Hotel

The presentation will be webcast live at the aforementioned time, and archived for 90 days thereafter, via the Investors section of company’s website at View Source, under Presentations & Events. Accessible at the same webpage, the presentation slides will be available during and after the conference.

In addition to making a presentation, management will also provide an overview of the company’s business in one-on-one meetings with investors who are registered to attend the conference.

On February 20, 2018 Diplomat Pharmacy, Inc. (NYSE: DPLO) reported that it will release its fourth quarter and 2017 year end financial results and provide 2018 guidance on Monday, February 26, 2018 after market close, with a conference call to follow at 5:00 p.m. ET (Press release, Diplomat Speciality Pharmacy, FEB 20, 2018, View Source [SID1234524096]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 833-640-6814 and referencing conference call ID 5992797 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of the Company’s website and an audio file of the call, as well as supplemental investor information, will be available for 90 days at ir.diplomat.is.

On February 20, 2018 ArQule, Inc. (Nasdaq: ARQL) reported it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018 (Press release, ArQule, FEB 20, 2018, View Source [SID1234524090]). The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast can be accessed in the "Investors and Media" section of our website, www.arqule.com, under "Events & Presentations." You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, www.arqule.com, under "Events and Presentations."

On February 20, 2018 Sangamo Therapeutics, Inc. (Nasdaq: SGMO) reported that the company will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, February 22, 2018 (Press release, Sangamo Therapeutics, FEB 20, 2018, View Source [SID1234524078]). The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 4392918. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 4392918.

On February 20, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that the Company’s scientists, and collaborators from the Mount Sinai School of Medicine, will present two abstracts at the American Chemical Society National Meeting & Expo (Press release, Onconova, FEB 20, 2018, View Source [SID1234524076]). The meeting is being held in New Orleans, LA, on March 18-22, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first abstract relates to the analysis of stability of the clinical product during storage and describes the synthesis and characterization of a de-sulfonylated product of rigosertib, Onconova’s lead phase 3 stage clinical candidate. The second abstract describes a new chemical entity ON 150030, which is a type 1 novel pre-clinical stage inhibitor of FLT3 and Src pathways, believed to be important for targeted therapy of relapsed and refractory AML.

Details for the poster presentations are listed below.

Title: Synthesis and characterization of de-sulfonylated product of rigosertib, a late phase III clinical candidate

Date: 18th March, 2018

Presentation Time: 7.00-9.00 PM CDT

Presenter: Dr. M.V. Ramana Reddy & Dr. Muralidhar Mallireddigari

Location: Ernest N. Morial Convention Center, Hall E.

Title: Discovery of a novel kinase inhibitor ON 150030, a type 1 inhibitor for relapsed and refractory AML

Date: 18th March, 2018

Presentation Time: 7.00-9.00 PM CDT

Presenter: Dr. M.V. Ramana Reddy

Location: Ernest N. Morial Convention Center, Hall E.